-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome -- -- Key Opinion Leaders (KOLs) participating on the call will include Theresa V. Strong, PhD., Jennifer L. Miller, MD, and Elizabeth Roof, H.S.P., M.A. -- -- Strong pre-clinical and clinical rationale supports potential of BMB 5-HT2C agonists to be the first on-target mechanism addressing bo ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter ended September 30, 2025. Third Quarter 2025 Key Financial Metrics1: Three Months EndedSeptember 30, Nine Months EndedSeptember 30,(in millions USD) 2025 2024 % Change 2025 </t ...

核心观点 - 公司2025年第三季度业绩表现强劲，营收和调整后EBITDA均实现显著增长，并上调了全年业绩指引 [2][8][13] - 公司成功完成债务再融资，优化了资本结构并延长了债务期限，增强了财务灵活性 [12][13] - 所有三个运营部门均展现出增长势头，特别是私人护理服务（PDS）部门贡献了主要营收增长 [2][3][36] 财务业绩摘要 - 第三季度营收为6.219亿美元，较去年同期的5.09亿美元增长22.2% [3][8] - 第三季度净利润为1410万美元，相比去年同期的净亏损4280万美元，实现扭亏为盈 [5][8] - 第三季度调整后EBITDA为8010万美元，较去年同期的4780万美元增长67.5%，利润率从9.4%提升至12.9% [2][6][8] - 前三季度营收为17.707亿美元，较去年同期的15.046亿美元增长17.7% [7] - 前三季度净利润为4630万美元，相比去年同期的净亏损4010万美元，实现大幅改善 [10] - 前三季度调整后EBITDA为2.359亿美元，较去年同期的1.284亿美元增长83.7%，利润率从8.5%提升至13.3% [11] 运营指标与部门表现 - 第三季度毛利率为32.6%，较去年同期的31.4%提升120个基点 [4][35] - 第三季度现场贡献（非GAAP指标）为1.074亿美元，现场贡献率为17.3%，较去年同期的14.0%显著提升 [35][40] - 私人护理服务（PDS）部门第三季度营收增长25.6%至5.144亿美元，服务时长增长12.9%，小时收入和价差均有提升 [36] - 家庭健康与临终关怀（HHH）部门第三季度营收增长15.3%至6240万美元，总入院人数和按服务项目付费的入院人数均有所增加 [37] - 医疗解决方案（MS）部门第三季度营收微降0.5%至4508万美元，但每位患者收入略有增长 [37] 现金流与资产负债表 - 截至2025年9月27日，公司拥有现金1.459亿美元，循环信贷额度未动用，借款能力约为2.27亿美元 [15] - 前三季度经营活动产生的净现金为7610万美元，自由现金流（非GAAP指标）为8620万美元 [15][46] - 总债务为14.9亿美元，公司通过利率互换和利率上限合约对冲了大部分利率风险 [15][33] 2025年全年业绩指引 - 将2025年全年营收指引从原先的超过23亿美元上调至超过23.75亿美元 [8][13][14][16] - 将2025年全年调整后EBITDA指引从原先的超过2.7亿美元上调至超过3亿美元 [8][13][14][16] 战略进展与管理层评论 - Thrive Skilled Pediatric Care的整合正按计划进行，预计在2025年底前完成 [2] - 管理层强调运营卓越、纪律严明的执行和强大的临床成果是业绩改善的驱动因素 [13] - 公司致力于为医疗复杂、高成本的患者群体提供高质量、高性价比的家庭护理服务 [2]

Third quarter revenues rose by 11% year-over-year to $2.3 billion, fueled by $590 million of Services revenues, up 12% compared to the same period last year, and 34 aircraft deliveries, up 4 units compared to the same quarter of 2024.Adjusted EBITDA(1) for the third quarter reached $356 million, marking a 16% year-over-year increase. The adjusted EBITDA margin(2) increased by 60 basis points to 15.4%. Reported EBIT for the quarter was $227 million.Adjusted net income(1) was $129 million, an increase of 59% ...

人事任命 - 公司任命Jessica Getman和Joe Siech为零售部门高级负责人 [1] - 新任命的两位高级负责人将负责推进战略重点 包括扩大运营规模以满足增长需求 培养创新文化以驱动差异化解决方案 以及投资于团队成长与发展 [2] - 此次人事任命旨在为零售部门领导团队注入新力量 以期释放新的业绩和进步机会 同时强化公司为客户和合作伙伴提供卓越价值的承诺 [2] 新任负责人背景 - Jessica Getman负责领导公司在太平洋西北地区的办公室 并为零售部门的战略计划做出贡献 [3] - Joe Siech领导公司的大型复杂商业团队 在保险行业拥有超过30年的经验 在全国销售领导和业务发展方面拥有良好的业绩记录 [3] 公司概况 - 公司是一家领先的保险经纪公司 自1939年以来提供全面和定制的保险解决方案及专业服务 [4] - 公司在全球拥有超过700个地点 团队由超过23,000名专业人员组成 [4]

Innovative and proprietary solution aims to set a new standard for high-efficiency performance while delivering superior economics and flexibility to operate on natural gas and renewable natural gas (“RNG”) as well as blends of natural gas, RNG and hydrogenVANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. (“Westport") (TSX:WPRT / Nasdaq: WPRT), a supplier of alternative fuel systems and components for the global transportation industry, today announces a breakthrough ...

Full-year 2025 outlook updated to reflect lower near-term EV production in North AmericaPyroThin® award from a major EU OEM demonstrates technology leadership & supports growth opportunitiesLNG and Subsea project opportunities expected to drive Energy Industrial growth in 2026 NORTHBOROUGH, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE: ASPN) (“Aspen” or the “Company”), a technology leader in sustainability and electrification solutions, today announced financial results for the third ...

EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced the pricing of an underwritten offering of 8,385,809 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,128,949 shares of commo ...

TEJON RANCH, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tejon Ranch Co., or the Company, (NYSE:TRC), a diversified real estate development and agribusiness company, today announced financial results for the three and nine-months ended September 30, 2025. Third Quarter 2025 Financial and Operating Highlights GAAP net income attributable to common stockholders for the third quarter of 2025 was $1.7 million, or net income per share attributable to common stockholders, basic and diluted, of $0.06. In the third q ...

Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical tech ...